Biocon gets USFDA EIR with VAI Classification for its Malaysian Insulin Manufacturing Facility Medical Dialogues Bureau1 April 2020 7:14 AM GMTBengaluru: Biocon Sdn Bhd, a subsidiary of Biocon Limited has announced that it has received the Establishment Inspection Report (EIR) from the U.S....
Biocon, Mylan win patent rights for Insulin Glargine Device against Sanofi Medical Dialogues Bureau12 March 2020 5:59 AM GMTInsulin Glargine is a long-acting insulin used to treat adults with Type 2 diabetes and adults and paediatric patients with Type 1 diabetes for the...
USFDA Accepts Biocon, Mylan's application for review of Proposed Biosimilar of Bevacizumab Medical Dialogues Bureau10 March 2020 7:45 AM GMTBiocon Ltd. and Mylan N.V. announced that the U.S. Food and Drug Administration (FDA) has accepted Mylan's Biologics License Application (BLA)...
Biocon Small Molecules API Manufacturing Facility Completes Post -Approval and GMP USFDA Inspection Medical Dialogues Bureau29 Feb 2020 6:05 AM GMTNew Delhi: Drug API maker, Biocon has informed that the U.S. Food and Drug Administration (FDA) conducted a Post-Approval and GMP inspection of Small...
Biocon Bengaluru facility clears USFDA inspection Farhat Nasim21 Jan 2020 7:30 AM GMT The US Food and Drug Administration (USFDA) conducted a pre-approval inspection of the oral solid dosage manufacturing facility of Biocon Pharma, a...
Biocon gets EIR from USFDA for Bengaluru biologics unit Medical Dialogues Bureau6 Nov 2019 3:49 AM GMTNew Delhi: Biopharmaceutical firm Biocon on Tuesday said it has received an establishment inspection report (EIR) from the US health regulator for its...
Biocon, Mylan launch insulin biosimilar Semglee in Australia Medical Dialogues Bureau3 Oct 2019 10:21 AM GMTNew Delhi: Biotechnology major Biocon and pharmaceutical company Mylan N V on Thursday announced the launch of their insulin biosimilar Semglee,...
Biocon gets USFDA Form 483 with 8 observations for 2 new facilities in Bengaluru Medical Dialogues Bureau23 Sep 2019 4:45 AM GMT"At the conclusion of the inspection, we received a Form 483 with four observations for the new Drug Substance facility, three observations for the...
Biocon Chief Kiran Shaw, FM Nirmala Sitharaman in tiff over E-Cigarette ban Farhat Nasim20 Sep 2019 11:31 AM GMTNew Delhi: Biocon Chief Kiran Mazumdar Shaw recently got into a spat with the Finance Minister Nirmala Sitharaman on Thursday. The minister defended...
Biocon inks license, supply pact with CMS for 3 generic formulations Medical Dialogues Bureau13 Sep 2019 9:15 AM GMTUnder the terms of the agreement, Biocon will be responsible for the development, manufacturing and supply of the products and China Medical System...
We need measures to save jobs in Automotive Sector: Biocon MD Kiran Mazumdar Shaw Medical Dialogues Bureau11 Sep 2019 4:00 AM GMT"Passenger Vehicle Sales See Worst Ever Monthly Drop Since 1997-98 - we need measures that r not abt saving auto sector but abt saving 50% of...
Syngene, Narayana Health, AIF launch CHAMPS- unique initiative to prevent, manage early onset of NCDs Medical Dialogues Bureau15 Aug 2019 4:00 AM GMTThe combined synergies of Narayana Health as a knowledge partner, Syngene and Biocon Foundation as funding partners and Agastya International as the...
